Effectiveness of Osmotic-Controlled Release Oral Delivery System Methylphenidate in the Treatment of Stuttering that Combined with Attention-Deficit/Hyperactivity Disorder: A Case Report
American Journal of Psychiatry and Neuroscience
Volume 2, Issue 6, November 2014, Pages: 115-117
Received: Dec. 15, 2014; Accepted: Dec. 22, 2014; Published: Dec. 27, 2014
Views 2523      Downloads 115
Authors
Sahin Bodur , Child and Adolescent Psychiatry, Dr. Sami Ulus Maternity and Children's Health and Diseases Training and Research Hospital, Ankara, Turkey
Yetis Isildar , Child and Adolescent Psychiatry, Dr. Sami Ulus Maternity and Children's Health and Diseases Training and Research Hospital, Ankara, Turkey
Halil Kara , Child and Adolescent Psychiatry, Dr. Sami Ulus Maternity and Children's Health and Diseases Training and Research Hospital, Ankara, Turkey
Murat Sabanci , Child and Adolescent Psychiatry, Dr. Sami Ulus Maternity and Children's Health and Diseases Training and Research Hospital, Ankara, Turkey
Article Tools
Follow on us
Abstract
Attention-Deficit/Hyperactivity Disorder (ADHD) is the most common neurodevelopmental disorder in children that shows comorbidity with several psychopathology included stuttering. The prefrontal cortex is the area of brain that sends and receives projections from virtually all cortical sensory systems, motor systems, and many subcortical structures. It has been shown that psychostimulant medication increases activation of the inferior prefrontal cortex and the basal ganglia. Both functional neuroimaging and neuropsychological studies show that psychostimulant medication improves executive functions. Verbal fluency is also considered as one of the executive functions. In this article, we report osmotic-controlled release oral delivery system (OROS) methylphenidate treatment effectiveness of stuttering that combined with ADHD.
Keywords
ADHD, Stuttering, Psychostimulants, Treatment
To cite this article
Sahin Bodur , Yetis Isildar , Halil Kara , Murat Sabanci , Effectiveness of Osmotic-Controlled Release Oral Delivery System Methylphenidate in the Treatment of Stuttering that Combined with Attention-Deficit/Hyperactivity Disorder: A Case Report, American Journal of Psychiatry and Neuroscience. Vol. 2, No. 6, 2014, pp. 115-117. doi: 10.11648/j.ajpn.20140206.16
References
[1]
Kotte A, Faraone SV, Biederman J. Association of genetic risk severity with ADHD clinical characteristics. Am J Med Genet B Neuropsychiatr Genet. 2013;7:718-33.
[2]
Generali JA, Cada DJ. Risperidone: Stuttering. Hosp Pharm. 2014; 49:242-3.
[3]
Devroey D, Beerens G,Van De Vijver E. Methylphenidate as a treatment for stuttering: a case report. Eur Rev Med Pharmacol Sci. 2012;16: 66-69
[4]
Shaygannejad V, Khatoonabadi SA , Shafiei B, Ghasemi M, Fatehi F, Meamar R et al. Olanzapine Versus Haloperidol: Which Can Control Stuttering Better? Int J Prev Med. May 2013; 4: 270–273.
[5]
Donaher J, Richels C. Traits of attention deficit/hyperactivity disorder in school-age children who stutter. J Fluency Disord. 2012;37:242-52.
[6]
Arnsten AF, Wang MJ, Paspalas CD. Neuromodulation of thought: flexibilities and vulnerabilities in prefrontal cortical network synapses. Neuron. 2012; 76:223-39.
[7]
Arnsten AF. Catecholamine influences on dorsolateral prefrontal cortical networks. Biol Psychiatry. 2011;15;69:89-99.
[8]
Arnsten AF, Pliszka SR. Catecholamine influences on prefrontal cortical function: relevance to treatment of attention deficit/hyperactivity disorder and related disorders. Pharmacol Biochem Behav. 2011;99:211-6.
ADDRESS
Science Publishing Group
1 Rockefeller Plaza,
10th and 11th Floors,
New York, NY 10020
U.S.A.
Tel: (001)347-983-5186